carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02', 'lcsm,(-blcsm)', 'sclc']
 presents the results of skyscraper-02 - targeting tigit in es-#sclc does not appear to provide benefit #asco22 #lcsm 
Scientist on a mission against #cancer and #COVID19. VP, Global Engagement and Patient Partnerships @LUNGevity. Science is my calling, people are my passion.